美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SeaStar Medical Holding Corporation

0.0191

+0.00105.53%

成交量：8.04萬

成交額：1,569

市值：53.32萬

市盈率：-0.01

高：0.0200

開：0.0180

低：0.0180

收：0.0181

52周最高：0.0750

52周最低：0.0084

股本：2,791.46萬

流通股本：2,791.46萬

量比：6.81

換手率：0.29%

股息：- -

股息率：- -

每股收益(TTM):-1.6425

淨資產收益率：-302.01%

總資產收益率：-79.24%

市淨率：0.07

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

SeaStar Medical Holding Corporation

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.seastarmedical.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

SeaStar Medical Holding Corp最初於2007年6月6日以Nephrion，Inc.的名義在特拉華州註冊成立。2007年8月3日，公司更名為CytoPherx公司。2019年6月19日，在一項合併交易中，CytoPherx公司更名為SeaStar Medical公司，SeaStar Medical公司是一家醫療技術公司，主要專註於開發和商業化其主要候選產品，選擇性細胞異位裝置（“SCD”），用於兒童和成人急性腎損傷（“AKI”）適應症。SeaStar Medical目前正在完成一項關於SCD的人道主義設備豁免（“HDE”）的提交，用於治療持續腎替代療法（“CRRT”）的兒童AKI患者，並完成一項針對CRRT成人AKI患者的關鍵試驗的設計。SCD於2022年4月29日獲得美國食品和藥物管理局（“FDA”）的突破性設備指定，用於治療18歲及以上AKI成人患者的免疫調節失調。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ICUCW/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ICUCW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ICUCW\",,,,,undefined,":{"symbol":"ICUCW","market":"US","secType":"STK","nameCN":"SeaStar Medical Holding Corporation","latestPrice":0.019101,"timestamp":1782244800000,"preClose":0.0181,"halted":0,"volume":80361,"delay":0,"changeRate":0.055303867403314826,"floatShares":27914598,"shares":27914598,"eps":-1.6425,"marketStatus":"盤前交易","change":0.001001,"latestTime":"06-24 05:35:00 EDT","open":0.017999,"high":0.02,"low":0.017999,"amount":1569,"amplitude":0.110552,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.6425,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1782307800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.018,"volumeRatio":6.807023837215571},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ICUCW\",,,,,undefined,":{"symbol":"ICUCW","floatShares":27914598,"roa":"-79.24%","roe":"-302.01%","lyrEps":0,"volumeRatio":6.807023837215571,"shares":27914598,"dividePrice":0,"high":0.02,"amplitude":0.110552,"preClose":0.0181,"low":0.017999,"week52Low":0.0084,"pbRate":"0.07","psRate":"0.37","week52High":0.075,"institutionHeld":0,"latestPrice":0.019101,"eps":-1.6425,"divideRate":0,"volume":80361,"delay":0,"ttmEps":-1.6425,"open":0.017999,"prevYearClose":0.0113,"prevWeekClose":0.0162,"prevMonthClose":0.0158,"prevQuarterClose":0.0288,"fiveDayClose":0.0182,"twentyDayClose":0.0184,"sixtyDayClose":0.028},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ICUCW\",params:#limit:5,,,undefined,":[{"date":"2026-03-25","symbol":"ICUCW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774468800000,"name":null,"time":"盤後","dateTimestamp":1774411200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ICUCW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ICUCW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.seastarmedical.com","stockEarnings":[{"period":"1week","weight":0.1938},{"period":"1month","weight":0.0381},{"period":"3month","weight":-0.1622},{"period":"6month","weight":0.9101},{"period":"1year","weight":-0.0728},{"period":"ytd","weight":0.6904}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0162},{"period":"3month","weight":0.1169},{"period":"6month","weight":0.0626},{"period":"1year","weight":0.2223},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"SeaStar Medical Holding Corp最初於2007年6月6日以Nephrion，Inc.的名義在特拉華州註冊成立。2007年8月3日，公司更名為CytoPherx公司。2019年6月19日，在一項合併交易中，CytoPherx公司更名為SeaStar Medical公司，SeaStar Medical公司是一家醫療技術公司，主要專註於開發和商業化其主要候選產品，選擇性細胞異位裝置（“SCD”），用於兒童和成人急性腎損傷（“AKI”）適應症。SeaStar Medical目前正在完成一項關於SCD的人道主義設備豁免（“HDE”）的提交，用於治療持續腎替代療法（“CRRT”）的兒童AKI患者，並完成一項針對CRRT成人AKI患者的關鍵試驗的設計。SCD於2022年4月29日獲得美國食品和藥物管理局（“FDA”）的突破性設備指定，用於治療18歲及以上AKI成人患者的免疫調節失調。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.807433},{"month":2,"riseRate":0.6,"avgChangeRate":0.046821},{"month":3,"riseRate":0.6,"avgChangeRate":-0.024028},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.197386},{"month":5,"riseRate":0,"avgChangeRate":-0.176513},{"month":6,"riseRate":0.5,"avgChangeRate":-0.032975},{"month":7,"riseRate":0.6,"avgChangeRate":0.163583},{"month":8,"riseRate":0.2,"avgChangeRate":-0.152907},{"month":9,"riseRate":0.4,"avgChangeRate":-0.100305},{"month":10,"riseRate":0.8,"avgChangeRate":0.602108},{"month":11,"riseRate":0.4,"avgChangeRate":-0.176512},{"month":12,"riseRate":0,"avgChangeRate":-0.181163}],"exchange":"NASDAQ","name":"SeaStar Medical Holding Corporation","nameEN":"SeaStar Medical Holding Corporation"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ICUCW\",market:\"US\",,,undefined,":null}}